Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Goupille

Showing results (61-70 of 128) with videos related to

Pageof 13
Sort By:
Arthritis Research & Therapy|February 14, 2006
Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritisOlivier Meyer, Pascale Nicaise-Roland, Marie Dos Santos, et al.
Rheumatology (Oxford, England)|July 16, 2021
Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohortLaura Pina Vegas, Emilie Sbidian, Daniel Wendling, et al.
Mabs|September 3, 2016
The underlying inflammatory chronic disease influences infliximab pharmacokineticsChristophe Passot, Denis Mulleman, Theodora Bejan-Angoulvant, et al.
RMD Open|March 15, 2023
Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)Maxime Dougados, Julien Lucas, Emilie Desfleurs, et al.
RMD Open|March 18, 2022
Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in FranceMaxime Dougados, Julien Lucas, Emilie Desfleurs, et al.
Pharmaceutics|November 27, 2021
Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) ModelDavid Ternant, Olivier Le Tilly, Laurence Picon, et al.
Joint Bone Spine|September 22, 2014
Management of osteoporosis in women after forearm fracture: data from a French health insurance databaseFlorence Erny, Aurélie Auvinet, Delphine Chu Miow Lin, et al.
Clinical and Translational Science|February 27, 2020
Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid ArthritisStéphane Paul, Hubert Marotte, Arthur Kavanaugh, et al.
Therapeutic Drug Monitoring|March 11, 2010
Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritisDenis Mulleman, Delphine Chu Miow Lin, Emilie Ducourau, et al.
RMD Open|March 1, 2024
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA studyMaxime Dougados, Audrey Lardy-Cléaud, Emilie Desfleurs, et al.
Pageof 13

Showing results (61-70 of 128) with videos related to

Sort By:
Pageof 13
Arthritis Research & Therapy|February 14, 2006
Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritisOlivier Meyer, Pascale Nicaise-Roland, Marie Dos Santos, et al.
Rheumatology (Oxford, England)|July 16, 2021
Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohortLaura Pina Vegas, Emilie Sbidian, Daniel Wendling, et al.
Mabs|September 3, 2016
The underlying inflammatory chronic disease influences infliximab pharmacokineticsChristophe Passot, Denis Mulleman, Theodora Bejan-Angoulvant, et al.
RMD Open|March 15, 2023
Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)Maxime Dougados, Julien Lucas, Emilie Desfleurs, et al.
RMD Open|March 18, 2022
Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in FranceMaxime Dougados, Julien Lucas, Emilie Desfleurs, et al.
Pharmaceutics|November 27, 2021
Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) ModelDavid Ternant, Olivier Le Tilly, Laurence Picon, et al.
Joint Bone Spine|September 22, 2014
Management of osteoporosis in women after forearm fracture: data from a French health insurance databaseFlorence Erny, Aurélie Auvinet, Delphine Chu Miow Lin, et al.
Clinical and Translational Science|February 27, 2020
Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid ArthritisStéphane Paul, Hubert Marotte, Arthur Kavanaugh, et al.
Therapeutic Drug Monitoring|March 11, 2010
Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritisDenis Mulleman, Delphine Chu Miow Lin, Emilie Ducourau, et al.
RMD Open|March 1, 2024
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA studyMaxime Dougados, Audrey Lardy-Cléaud, Emilie Desfleurs, et al.
Pageof 13